Amgen Share Price Hits New Highs Amid Earnings Beat and Raised Guidance

Amgen's recent Q2 earnings report and raised guidance have led to a significant increase in its share price, with a 15.46% one-month return and a 27.02% year-to-date return. The company's five-year total shareholder return stands at 113.11%, indicating sustained long-term gains. However, some analysts suggest that Amgen may be overvalued by around 15.6%, with a narrative fair value of $359.98 compared to its current share price of $416.18.

The 'Amgen 2027 Bull Case' relies on several assumptions, including macro obesity market growth and FDA tailwinds, which are expected to trigger a re-rating. However, this narrative leans heavily on specific revenue growth, margin assumptions, and future earnings multiple forecasts that may not materialize.

A discounted cash flow model developed by Simply Wall St estimates Amgen's fair value at $654.75, which is 36.4% above the current share price and suggests that the company is undervalued.